Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAINRITSyS: Rituximab vs Placebo for Maintenance in SSc-ILD
NCT07827742Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2026
- Primary completion
- May 2030
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) and interstitial lung disease (ILD) comparing Rituximab with Placebo (2 arms). Primary endpoint: Forced Vital Capacity at 18 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
systemic sclerosis (SSc)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07827742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07827742.